Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Open Label, Multicenter, Exploratory Study to Assess Changes in Joint Inflammation Using Ultrasonography in Subjects With Rheumatoid Arthritis Treated for 12 Weeks With Certolizumab Pegol

NCT01292265 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT01292265
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01292265 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Open Label, Multicenter, Exploratory Study to Assess Changes in Joint Inflammation Using Ultrasonography in Subjects With Rheumatoid Arthritis Treated for 12 Weeks With Certolizumab Pegol
Lead sponsor
UCB Pharma
Phase
Phase 3
Overall status
Terminated
Start date
February 28, 2011
Completion date
January 31, 2012
Enrollment
3 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis